Evidence map›Paper›PMID 42384912›Full record

ArticleRheumatology (Oxford, England)2026

Radiographic sacroiliitis progression in psoriatic arthritis.

Virginia Carrizo-Abarza, Pankti Mehta, Fadi Kharouf, Shangyi Gao, Richard J Cook, Dafna D Gladman, Vinod Chandran, Denis Poddubnyy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Virginia Carrizo-AbarzaGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.
Pankti MehtaGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.
Fadi KharoufGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-3540-0341
Shangyi GaoGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.
Richard J CookDepartment of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada.ORCID 0000-0002-1414-4908
Dafna D GladmanGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-9074-0592
Vinod ChandranGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.
Denis PoddubnyyGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.

Funding

Krembil foundationKrembil Foundation and the Schroeder Arthritis Institute. V.C
6 · The paper itself

Abstract

objectiveTo assess radiographic sacroiliitis progression in PsA and factors associated with it.

methodsWe analysed a prospective PsA cohort (1978-2025). Pelvic radiographs were obtained biannually. Change (Δ) in the sacroiliitis sum score (SSS, 0-8; left + right modified New York-mNY-grades) was the primary outcome, while patients with SSS = 8 at baseline were excluded from the analyses. Linear mixed-effects models assessed factors associated with ΔSSS over successive clinic visits. As a secondary outcome, time to incident mNY sacroiliitis was evaluated with Cox regression.

resultsAmong 1554 eligible patients (median follow-up 6.00 years), 475/1056 (45%) showed progression in SSS by at least one grade. In univariable analyses, male sex, 66-joint swollen count, PASI, nail disease, syndesmophytes, abnormal ESR/CRP and higher DAPSA were associated with progression, while older age and longer PsA duration were associated with less progression. Biologic/targeted synthetic (b/ts) DMARD exposure and follow-up in the post-2011 era were associated with lower progression rates. In multivariable models, older age and b/tsDMARD exposure retained protective associations. Among 831 patients without definite mNY sacroiliitis at baseline and with ≥1 follow-up radiograph, 189 (22.7%) developed definite mNY sacroiliitis. In univariable Cox analysis, nail disease, higher PASI, abnormal ESR/CRP, higher DAPSA and syndesmophytes were associated with progression, while b/tsDMARD exposure and later eras were associated with lower progression; effects were attenuated after adjustment.

conclusionRadiographic sacroiliitis progression is common in PsA. Greater inflammatory activity increased risk, whereas b/tsDMARD exposure were protective; progression was lower in the modern treatment era.

Indexed as

Arthritis, PsoriaticSacroiliitisAdultAntirheumatic AgentsDisease ProgressionFemaleHumansMaleMiddle AgedProspective StudiesRadiographySeverity of Illness IndexAntirheumatic Agentsaxial diseasePsAradiographic progressionsacroiliitis

Identifiers

PMID42384912
PMCPMC13342714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.